Anzeige
Erschienen in:
12.08.2024 | Sarcoma
Evolution of Initial Treatment for Desmoid Tumors
verfasst von: Alex J. Bartholomew, MD, Kristen E. Rhodin, MD, Laura Noteware, BS, Dimitrios Moris, MD, Elishama Kanu, MD, Sabran Masoud, MD, T. Clark Howell, MD, Danielle Burner, BS, Charles Y. Kim, MD, Daniel P. Nussbaum, MD, Sabino Zani, MD, Michael E. Lidsky, MD, Peter J. Allen, MD, Richard F. Riedel, MD, Dan G. Blazer III, MD
Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Desmoid tumors (DTs) are rare, fibroblastic cell proliferations that can exhibit locally aggressive behavior but lack metastatic potential. Initial management has traditionally involved upfront resection; however, contemporary guidelines and expert panels have increasingly advocated for prioritizing active surveillance strategies.
Methods
A single-institution, retrospective chart review identified all patients diagnosed with a primary DT at any site from 2007 to 2020. The primary outcome was the initial management strategy over time. Secondary outcomes included treatment-free survival (TFS) and time to treatment (TTT) for those undergoing active surveillance, as well as recurrence-free survival (RFS) and time to recurrence for those undergoing resection.
Results
Overall, 103 patients were included, with 68% female and a median follow-up of 44 months [24–74]. The most common tumor locations included the abdominal wall (27%), intra-abdominal/mesenteric (25%), chest wall (19%), and extremity (10%). Initial management included resection (60%), systemic therapy (20%), active surveillance (18%), and cryoablation (2%). Rates of surgical resection significantly decreased (p < 0.001) over time, from 69.6% prior to 2018 to 29.2% after 2018. For those treated with upfront resection, 5-year RFS was 41.2%, and for patients undergoing initial active surveillance, TFS was 66.7% at 2 years, with a median TTT of 4 months [4–10].
Conclusions
This single-institution cohort at a tertiary medical center spanning over a decade demonstrates the transition to active surveillance for initial management of DTs, and highlights salient metrics in the era of surveillance. This trend mirrors recommended treatment strategies by expert panels and consensus guidelines.
